The companies made this decision after evaluating the recent results from an interim analysis of pooled data intended for a possible extension of the ongoing clinical phase III trial programme.
Efficacy data did not support pursuing the existing development strategy of stabilisation of non-acute patients with schizophrenia.
Therefore, Lundbeck and Solvay judge that it would be futile to continue the studies.
2 comments:
The gossip on cafepharma and Yahoo is that Lundbeck has bought Vanda and Fanapt and doesn't need a schizo drug anymore.
Vanda is hosting a conf call on monday aug 10, they might announce the buyout if its done
Post a Comment